The Alcatraz‐Strategy: a roadmap to break the connectivity barrier in malignant brain tumours
Molecular Oncology · 2024-12 · 18 (12) · 2890-2905
DOI: 10.1002/1878-0261.13642 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 03.04.2024. Verfasst von Matthias Schneider und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Hospital Bonn, Germany. Hauptthemen laut MEDLINE: Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mildred Scheel School of Oncology, German Cancer Aid, Ministry of Culture and Science of the State of Nordrhein-Westfalen.
Abstract (Originalsprache)
In recent years, the discovery of functional and communicative cellular tumour networks has led to a new understanding of malignant primary brain tumours. In this review, the authors shed light on the diverse nature of cell‐to‐cell connections in brain tumours and propose an innovative treatment approach to address the detrimental connectivity of these networks. The proposed therapeutic outlook revolves around three main strategies: (a) supramarginal resection removing a substantial portion of the communicating tumour cell front far beyond the gadolinium‐enhancing tumour mass, (b) morphological isolation at the single cell level disrupting structural cell‐to‐cell contacts facilitated by elongated cellular membrane protrusions known as tumour microtubes (TMs), and (c) functional isolation at the single cell level blocking TM‐mediated intercellular cytosolic exchange and inhibiting neuronal excitatory input into the malignant network. We draw an analogy between the proposed therapeutic outlook and the Alcatraz Federal Penitentiary, where inmates faced an impassable sea barrier and experienced both spatial and functional isolation within individual cells. Based on current translational efforts and ongoing clinical trials, we propose the Alcatraz‐Strategy as a promising framework to tackle the harmful effects of cellular brain tumour networks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, University Hospital Bonn, Germany.
- Brain Tumour Translational Research Group, University Hospital Bonn, Germany.
- Department of Neurosurgery, University Medical Center Ulm, Germany.
- Department of Neurosurgery, BG Klinikum Unfallkrankenhaus Berlin gGmbH, Germany.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
- Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.
ORCID-Profile: Matthias Schneider, Anna-Laura Potthoff, Ulrich Herrlinger
Förderung
- Mildred Scheel School of Oncology
- German Cancer Aid
- Ministry of Culture and Science of the State of Nordrhein-Westfalen
- German Ministry of Education and Research
- Deutsche Krebshilfe
Zitieren
APA
Schneider, M., Potthoff, A. L., Karpel-Massler, G., Schuss, P., Siegelin, M. D., Debatin, K. M., Duffau, H., Vatter, H., Herrlinger, U., & Westhoff, M. A. (2024). The Alcatraz‐Strategy: a roadmap to break the connectivity barrier in malignant brain tumours. Molecular Oncology, 18(12), 2890-2905. https://doi.org/10.1002/1878-0261.13642
Vancouver
Schneider M, Potthoff AL, Karpel-Massler G, Schuss P, Siegelin MD, Debatin KM, et al. The Alcatraz‐Strategy: a roadmap to break the connectivity barrier in malignant brain tumours. Molecular Oncology. 2024;18(12):2890-2905. doi:10.1002/1878-0261.13642
BibTeX
@article{Schneider2024,
author = {Schneider, Matthias and Potthoff, Anna-Laura and Karpel-Massler, Georg and Schuss, Patrick and Siegelin, Markus D and Debatin, Klaus-Michael and Duffau, Hugues and Vatter, Hartmut and Herrlinger, Ulrich and Westhoff, Mike-Andrew},
title = {The Alcatraz‐Strategy: a roadmap to break the connectivity barrier in malignant brain tumours},
journal = {Molecular Oncology},
year = {2024},
volume = {18},
number = {12},
pages = {2890--2905},
doi = {10.1002/1878-0261.13642}
}
EUVIMED